| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CFTR corrector 9 targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is a chloride channel that is defective in cystic fibrosis due to mutations that cause misfolding and impaired trafficking to the cell surface. CFTR correctors are small molecules that help to correct the folding and trafficking of mutant CFTR, increasing the amount of functional protein at the cell surface.
|
|---|---|
| ln Vitro |
In vitro, CFTR corrector 9 functions as a CFTR modulator. It has been shown to modulate miRNAs, activate the Rab9 and NPC1 promoters, enhance SMN2 splice variant expression, and inhibit ROR gamma transcriptional activity. Specific EC50 or IC50 values for its CFTR correcting activity are not provided in the available sources.
|
| ln Vivo |
Specific in vivo activity data for CFTR corrector 9 are not provided in the available sources. As a CFTR modulator, it would be expected to have effects in animal models of cystic fibrosis. However, no specific in vivo studies, dosing regimens, or efficacy data are described in the references cited. The compound is primarily utilized as a research tool for in vitro studies.
|
| Enzyme Assay |
A cell-free assay for CFTR corrector 9 is not applicable as it functions as a modulator of protein folding and trafficking, which are cellular processes. Its activity is typically assessed in cell-based assays measuring CFTR function.
|
| Cell Assay |
Cellular assays for CFTR corrector 9 typically involve measuring its ability to increase the function of mutant CFTR in cells. Cells expressing mutant CFTR are treated with the compound, and CFTR-mediated chloride transport is measured using techniques such as the halide-sensitive yellow fluorescent protein (YFP) assay or patch-clamp electrophysiology. The compound's ability to increase CFTR expression at the cell surface can also be assessed by Western blotting or immunofluorescence.
|
| Animal Protocol |
In vivo animal experiments for CFTR corrector 9 are not described in the available sources. As a CFTR modulator, it could be evaluated in animal models of cystic fibrosis, such as the CFTR-knockout mouse or the ferret model. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
CFTR corrector 9 has a molecular formula of C16H14N2O4 and a molecular weight of 298.29 g/mol. Its CAS number is 909861-78-5. Specific pharmacokinetic parameters, such as half-life and bioavailability, are not provided in the available sources. As a research compound, it is intended for preclinical studies. For storage, the powder should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for CFTR corrector 9 are not provided in the available sources. As a research compound, it is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
N-(2-furanmethyl)-5-(3-methoxyphenyl)-3-isoxazolecarboxamide is a member of the methoxyphenyl class of compounds.
CFTR corrector 9 (CAS: 909861-78-5) is a CFTR modulator. It is also known as compound 42. The compound is used in research on cystic fibrosis and other CFTR-related disorders. It is not an approved drug and is strictly for research purposes. |
| Molecular Formula |
C16H14N2O4
|
|---|---|
| Molecular Weight |
298.29
|
| Exact Mass |
298.095
|
| CAS # |
909861-78-5
|
| PubChem CID |
3244363
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
379
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2=CC=CC(OC)=C2)=CC(C(NCC2=CC=CO2)=O)=N1
|
| InChi Key |
VLTZRGPEWQWHCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2O4/c1-20-12-5-2-4-11(8-12)15-9-14(18-22-15)16(19)17-10-13-6-3-7-21-13/h2-9H,10H2,1H3,(H,17,19)
|
| Chemical Name |
N-(furan-2-ylmethyl)-5-(3-methoxyphenyl)-1,2-oxazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~419.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3524 mL | 16.7622 mL | 33.5244 mL | |
| 5 mM | 0.6705 mL | 3.3524 mL | 6.7049 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
